Table 1.
Model parameterization for the base-case and probabilistic sensitivity analysis.
| Parameter | Base | Sample distribution for probabilistic sensitivity analysis | References | |
|---|---|---|---|---|
| HCV-viremic organ prevalence among heart donors (%) | 4.9% | Uniform (min=2.5, max= 7.3) | ||
| Monthly Transition Probabilities | ||||
| Inotropes | VAD | 0.0084 | Sampled annual rate uniformly +/− 50% (min=0.051, max=0.152) | 27,28 |
| Transplant (HCV Negative organ) | 0.2330 | Sampled WL time in months uniformly +/− 50% (min=1.9; max=5.7) and converted to TP | 3 | |
| Death | 0.0740 | Sampled annual rate uniformly +/− 50% (min=0.461; max=1.384) | 33,34 | |
| VAD | Complications/Delist | 0.0760 | Sampled annual rate uniformly +/− 50% (min=0.474; max=1.423) | 31,33 |
| Transplant (HCV Negative organ) | 0.1123 | Sampled WL time in months uniformly +/− 50% (min=4.2, max=12.6) and converted to TP | 3 | |
| Death | 0.009 | Sampled annual rate uniformly +/− 50% (min=0.054, max=0.163) | 31,33,86 | |
| Complications | Death | 0.64 | Sampled annual rate uniformly +/− 50% (min=6.13, max=18.390) | 33 |
| Transplant Yr1 | Death | 0.0076 | Sampled annual rate uniformly +/− 50% (min=0.077, max=0.096) | 3,87 |
| Transplant Yr2+ | Death | 0.0020 | Sampled annual rate uniformly +/− 50% (min=0.023, max=0.025) | 3,87 |
| F0 | F1 | 0.0109 | Sampled annual rate from Beta (α=446.989, β=2906.45), converted to monthly TP | 36,42 |
| F1 | F2 | 0.0074 | Sampled annual rate from Beta (α=394.323, β=3971.41), converted to monthly TP | 36,42 |
| F2 | F3 | 0.0109 | Sampled annual rate from Beta (α=2.852, β=44.384), converted to monthly TP | 36,42 |
| F3 | F4 | 0.0105 | Sampled annual rate from Beta α=666.175, β=4584.86), converted to monthly TP | 36,42 |
| CC | DC | 0.0055 | Sampled annual rate from Beta (α=33.587, β=487.785), converted to monthly TP | 36,39 |
| CC | HCC | 0.0017 | Sampled annual rate from Beta (α=12.959, β=617.161), converted to monthly TP | 36,37 |
| DC | Liver Death | 0.0151 | Sampled annual rate from Beta (α=8.5332, β=26.132), converted to monthly TP | 38,39 |
| DC | HCC | 0.0058 | Sampled annual rate from Beta (α=18.953, β=263.478), converted to monthly TP | 39–41 |
| HCC | Liver Death | 0.0742 | Sampled annual rate from Beta (α=7.597, β=6.016), converted to monthly TP | 38,39,50,52 |
| Health State Utilities | ||||
| Inotropes | 0.53 | 33,50,52 | ||
| VAD | 0.72 | 31,33,52,55 | ||
| Complications | 0.63 | 33,62 | ||
| Heart Transplant | 0.76 | 33,52 | ||
| F0-F2 | 0.53 | 64,65,88 | ||
| F3-F4 | 0.42 | 64,65,88 | ||
| DC | 0.21 | 64,65,88 | ||
| HCC | 0.21 | 64,65,88 | ||
| Costs (2018 USD$) | ||||
| Inotrope therapy (monthly) | 5668 | Uniform +/− 50% point value | 33,50,51 | |
| VAD Index Hospitalization | 307593 | Uniform +/− 50% point value | 33,44,45,49,53,55,58 | |
| Post-VAD care (monthly) | 14136 | Uniform +/− 50% point value | 33,47,48,55,56 | |
| VAD Complication (one-time cost) | 21800 | Uniform +/− 50% point value | 33,45,46,53,54 | |
| Heart Transplant Index Hospitalization | 251232 | Uniform +/− 50% point value | 33,49 | |
| Post-Transplant Care (monthly) | 13337 | Uniform +/− 50% point value | 33,48,56 | |
| DAA 12-week course | 39600 | Uniform +/− 50% point value | 19,89 | |
| Chronic HCV F0-F2 (monthly) | 252 | Uniform +/− 50% point value | 59,61 | |
| Chronic HCV F3 (monthly) | 453 | Uniform +/− 50% point value | 59,61 | |
| Compensated Cirrhosis/F4 (monthly) | 854 | Uniform +/− 50% point value | 36 | |
| Decompensated Cirrhosis (monthly) | 2906 | Uniform +/− 50% point value | 36,60 | |
| HCC (monthly) | 4637 | Uniform +/− 50% point value | 36,60 | |
VAD=ventricular assist device; METAVIR F0-F4; CC=compensated cirrhosis; DC=decompensated cirrhosis; HCC=hepatocellular carcinoma